Meridian Malaria Test Wins Prestigious Innovation Award

ID: 1455230
recent pressrelease next pressrelease

(Thomson Reuters ONE) -

illumigene® Malaria Receives 1st Place Award at the
Journées Internationales de Biologie /Association des Colloques Nationaux des
Conference in Paris

CINCINNATI, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc.
(NASDAQ:VIVO) was awarded 1st place for innovation in emergency treatment and
point-of-care testing for its illumigene® Malaria test at the 2016 JIB/ACNBH
Conference this summer. Innovations from worldwide companies contributing to the
development of the Medical Biology industry were put under the spotlight at this
year''s conference held in Paris, France, and were reviewed by worldwide expert
members in the medical biology field.

The illumigene Malaria test is a major step forward in providing faster, more
accurate diagnoses that can lead to prompt treatment and better patient
outcomes, as malaria remains one of the top 3 killers of children globally,
claiming one life every minute of every day. The test is up to 400 times more
sensitive at detecting the malaria parasite than conventional tests, potentially
revolutionizing malaria diagnosis and establishing a new gold standard for both
the developed and developing world. By using molecular LAMP
technology,illumigene Malaria provides results in less than one hour, and does
not require refrigeration or heating of materials, nor a high level of technical

Professor Daouda Ndiaye, chief of the laboratory of parasitology and mycology at
Cheikh Anta Diop University in Senegal, who presented the test at the event,
commented; "This is not merely a scientific breakthrough. Faster and more
accurate diagnosis is vital in the fight against malaria. Because of
submicroscopic parasitemia carriage among the populations, a robust, sensitive

and field community-deployable screening tool is needed to track the malaria
reservoir in pre-elimination regions. The clinical trial I ran in Senegal for
the validation of the test shows that illumigene Malaria has this capacity."

Meridian''s product development strategy is driven by three core concepts-speed,
simplicity, and accuracy - that empowers healthcare providers around the world
to improve patient care. Slava Elagin, Executive Vice President Research &
Development for Meridian Bioscience, said, "We are delighted
that illumigene Malaria has been recognized as a breakthrough in emergency
treatment and point-of-care testing and we look forward to more illumigene tests
making a positive impact worldwide. We are evaluating a wide range of product
ideas to assess which ones have the greatest potential to become the next
breakthrough in diagnosis."

The illumigene Malaria test received the CE Mark in January of this year, and is
available in the European, Middle Eastern and African regions by Meridian
Bioscience Europe and in additional international markets by the Company''s
global distribution network. To read more about the JIB/ACNBH Medical Biology
award, please visit

Meridian is a fully integrated life science company that develops, manufactures,
markets and distributes a broad range of innovative diagnostic test kits,
purified reagents and related products and offers biopharmaceutical enabling
technologies. Utilizing a variety of methods, these products and diagnostic
tests provide accuracy, simplicity and speed in the early diagnosis and
treatment of common medical conditions, such as gastrointestinal, viral and
respiratory infections and blood lead levels. Meridian''s diagnostic products are
used outside of the human body and require little or no special equipment. The
Company''s products are designed to enhance patient well-being while reducing the
total outcome costs of health care. Meridian has strong market positions in the
areas of gastrointestinal and upper respiratory infections; serology,
parasitology and fungal disease diagnosis, and blood lead level testing. In
addition, Meridian is a supplier of rare reagents, specialty biologicals and
related technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and technologies to
hospitals, reference laboratories, research centers, diagnostics manufacturers
and biotech companies in more than 70 countries around the world. The Company''s
shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian''s
website address

For Additional information:
For more information about Meridian Bioscience Europe, please

Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Meridian Bioscience, Inc. via GlobeNewswire

More information: http:// htt

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 08/30/2016 - 10:09
Language: English
News-ID 1455230
Character count: 4159
Firma: Meridian Bioscience, Inc.
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Cincinnati


Number of hits: 185


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 433
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 51

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.